ADR: the number of shares per ADR isn’t known yetADR: the number of shares per ADR isn’t known yet, so we show no figure rather than a guess. Shares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily.CIK 1778016The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
1 buy · 7 sells
$154.3K sold, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in NovaBridge Biosciences's latest quarterly report, compared with the one before.
We have not read a recent 10-Q for this company yet.
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What NovaBridge Biosciences and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
35
11 added · 11 trimmed
Insider trades
8 in 12 mo
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No open-market insider trades reported since Sep 18, 2026. Insiders have two business days to file.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
35 funds report NBP. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Q3 2026. 5 new, 11 added to, 11 trimmed, 20 exited since Q2 2026.
Download CSVEvery fund that holds NBP, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What NovaBridge Biosciences and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q1 2020
16
—
4.68M
$60.8M
Q2 2020
20
+4
4.68M
$139.2M
Q3 2020
48
+28
9.53M
$447.7M
Q4 2020
65
+17
13.06M
$615.6M
Q1 2021
80
+15
23.32M
$1.1B
Q2 2021
136
+56
28.29M
$2.4B
Q3 2021
145
+9
36.07M
$2.6B
Q4 2021
132
-13
39.20M
$1.9B
Q1 2022
119
-13
40.36M
$658.1M
Q2 2022
97
-22
40.82M
$1.0B
Q3 2022
74
-23
28.54M
$114.4M
Q4 2022
69
-5
24.87M
$103.9M
Q1 2023
53
-16
20.70M
$71.6M
Q2 2023
48
-5
18.69M
$55.9M
Q3 2023
47
-1
15.25M
$20.1M
Q4 2023
44
-3
12.86M
$24.4M
Q1 2024
39
-5
12.21M
$22.7M
Q2 2024
38
-1
15.14M
$25.3M
Q3 2024
28
-10
14.19M
$17.6M
Q4 2024
28
0
11.91M
$10.1M
Q1 2025
29
+1
8.99M
$7.4M
Q2 2025
32
+3
9.40M
$22.7M
Q3 2025
42
+10
29.84M
$112.9M
Q4 2025
57
+15
33.20M
$132.1M
Q1 2026
48
-9
29.32M
$72.1M
Q2 2026
49
+1
24.67M
$48.1M
Q3 2026
35
-14
8.90M
$12.2M
Each point is a quarter-end, from Q1 2020 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (44975P103). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2020) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.